Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide LAR pilot study in hereditary hemorrhagic telangiectasia with gastrointestinal bleeding
NL-OMON43279Phase 2Active, not recruiting
- Sponsor
- Maag Lever Darm Stichting
- Start
- Dec 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of octreotide in hereditary hemorrhagic telangiectasia (HHT), sponsored by Maag Lever Darm Stichting. Primary endpoint: Treatment response. Started Dec 2016; status: active, not recruiting.
02
Drugs
octreotide
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NL-OMON43279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43279.